Dr Reddy'S Lab Shs Sponsored American Deposit Receipt Repr 1 Sh (NYSE:RDY) Q4 2020 Earnings Conference Call - Final Transcript

May 20, 2020 • 07:45 am ET


Dr Reddy'S Lab Shs Sponsored American Deposit Receipt Repr 1 Sh (NYSE:RDY) Q4 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Ladies and gentlemen. Good day and welcome to the Dr. Reddy's Q4 FY '20 Earnings Conference Call.

[Operator Instructions]

I now hand the conference over to Mr. Amit Agarwal. Thank you, and over to you, sir.

Amit Agarwal

Very good morning and good evening to all of you, and thank you for joining us today for the Dr. Reddy's earnings conference call for the quarter and full year ended 31 March 2020.

Earlier during the day, we have released our results and the same are also posted on our website. This call is being recorded, and the playback and transcript shall be made available on our website soon. All the discussions and analysis of this call will be based on the IFRS consolidated financial statements. To discuss the business performance and outlook, we have the leadership team of Dr. Reddy's comprising Mr. G V Prasad, our Co-Chairman and Managing Director, Mr. Erez Israeli, our CEO, Mr. Saumen Chakraborty, our CFO, and the Investor Relations team.

Please note that today's call is a copyrighted material of Dr. Reddy's, and cannot be rebroadcasted or attributed in press or media outlet without the company's expressed written consent.Before I proceed with the call, I would like to remind everyone that the safe harbor contained in today's press release also pertains to this conference call.

Now I hand over the call to Mr. G V Prasad. Over to you, sir.

G V Prasad

Thank you, Amit.

Good evening, good afternoon and good morning to all the participants. I do hope that you and your families continue to remain safe and healthy during these unprecedented times. Let me quickly provide you with an update on the situation and how we, as an organization, are playing a part within the overall health care system in these extraordinary times. Our foremost priority is to ensure the health and safety of our employees, patients, health care professionals, customers, suppliers and community at large. We have enhanced the safety requirements across all our working locations, enforced physical distancing norms, mandated use of protective gear, and enabled remote working across all our global office locations. We have accepted the new reality and swiftly implemented an effective business continuity plan across the functions and have been able to ensure that our operations continue right through the pandemic situation without compromising on the health and safety of our employees.

From a supply perspective, together with the inventory on hand and the continued manufacturing support, we have been able to address the enhanced product demands across various markets. We launched several new products, overcame logistical barriers and effective -- through effective customer engagement have continued the business. In the branded markets, we've been able to effectively leverage the virtual connect model to support health care professionals, patients and our people. Overall, we are truly inspired to see how colleagues across the company have risen to the occasion and overcome every obstacle in the way to fulfill our mission, which is to ensure continued supply medicines to patients and doctors under